Topic: pneumococcal vaccine
AZ's China sales jumped 25% in 2018; Pfizer Japan recalls valsartan drugs made with Mylan's API; resistance might hurt Shionogi and Roche's Xofluza.
In a phase 1/2 study, Astellas and Affinivax's MAPS-based vaccine will be tested head-to-head against Pfizer's Prevnar 13.
Merck's 15-strain pneumococcal vaccine got an FDA breakthrough tag for children, months after Pfizer's 20-valent shot won one in adults.
Racing to the market with rival Merck, Pfizer won an important FDA "breakthrough" tag for its next-gen pneumococcal vaccine candidate.
Merck is already in phase 3 testing for its next-generation pneumococcal vaccine, and Pfizer's CFO said his company is "all in" on advancing its shot.
Pfizer’s vaccines business has for years centered on Prevnar 13, the world’s bestselling vaccine, and 2017 was no exception. But the company wants to change that—and for good reason.
While immuno-oncology star Keytruda has generated plenty of headlines for Merck lately, the company's vaccine business has been on the upswing, too, thanks to human papillomavirus shot Gardasil 9.
Looking to take on global vaccine heavyweights, SutroVax revs up with Series C funding and a prominent new chairman.
Pfizer has three vaccine programs in development—and top executives have high hopes—but two key programs have competitors close behind.
Serum Institute of India plans to launch four vaccines in the coming years for pneumococcal, HPV, meningococcal and dengue.